Specificity: COV1-65 targets the N-terminal domain (NTD) of the SARS-CoV-1 prefusion spike protein, distributed on the viral surface. Antigen Distribution: Anti-SARS-CoV-1 recognizes antigens on infected cells, including respiratory epithelial cells. Background: SARS-CoV-1, also known as the Severe Acute Respiratory Syndrome coronavirus, is a zoonotic virus that is believed to have originated from an animal reservoir, possibly horseshoe bats, and transmitted to humans1. This virus primarily affects the respiratory system and can cause symptoms such as muscle pain, headache, fever, cough, dyspnea, and pneumonia1,2. It was the first severe and readily transmissible new disease to emerge in the 21st century, with the capacity to spread globally via international air travel. COV1-65 is a monoclonal antibody specific to the N-terminal domain (NTD) of the SARS-CoV-1 spike protein. Unlike antibodies targeting the RBD, COV1-65 does not block the ACE2 receptor but does function as a neutralizer. The NTD is important for the viruss structural integrity and function, and targeting this domain could disrupt the viral life cycle in other ways. COV1-65s binding to the NTD suggests it could be useful in inhibiting viral attachment or fusion indirectly or in combination with other neutralizing antibodies, providing a broader approach to preventing infection.
Clonality:
Monoclonal
Clone Designation:
[COV1-65]
Purity:
Purity: >=90% monomer by analytical SEC and SDS-Page Preparation: Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Target:
SARS-CoV-1
Application Dilute:
N
* VAT and and shipping costs not included. Errors and price changes excepted
